AbbVie Inc. (ABBV) Monday said its Phase 3 VERONA study evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary goal of overall survival (OS).
Venetoclax is already approved in over 80 countries including the U.S. for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is also approved in combination with azacitidine, or decitabine, or low-dose cytarabine to treat newly diagnosed acute myeloid leukemia (AML) in people who are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.